Last Updated : December 18, 2015
Details
FilesGeneric Name:
Panitumumab
Project Status:
Complete
Therapeutic Area:
Metastatic Colorectal Cancer
Manufacturer:
Amgen Canada Inc.
Brand Name:
Vectibix
Project Line:
Reimbursement Review
Project Number:
PC0060-000
Strength:
20mg/mL (100mg vial)
Tumour Type:
Gastrointestinal
Indications:
Metastatic Colorectal Cancer
Funding Request:
For the treatment of patients with WT RAS mCRC in first line treatment setting in combination with FOLFOX
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Amgen Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : December 18, 2015